The kratom industry is leveraging political connections to block federal regulation of the botanical substance, a move that stands to enrich cabinet allies with direct financial stakes in the market.
Markwayne Mullin, a Republican senator from Oklahoma who holds equity in a kratom company, and Robert F. Kennedy Jr., positioned for a health policy role in the Trump administration, have emerged as powerful backers of the unregulated plant. Kratom, derived from the Mitragyna speciosa tree, sells widely at gas stations and convenience stores across America despite containing alkaloids that produce opioid-like effects and carry documented addiction potential.
The substance occupies a regulatory gray zone. The FDA has not approved kratom for medical use and has warned consumers about its risks, including nausea, constipation, and psychological dependence. Yet kratom remains legal to buy and sell in most states, unregulated as a dietary supplement under current law. The industry generates substantial revenue without quality controls, dosing standards, or labeling requirements.
Mullin's ownership stake creates a direct financial incentive. His support amplifies industry messaging that frames regulation as government overreach, not consumer protection. Kennedy's alignment with the kratom cause signals potential policy resistance from within a new health administration, where he could shape FDA positioning and drug scheduling decisions.
The political maneuver reflects a broader pattern. Industries threatened by regulation recruit sympathetic lawmakers and appointees to block enforcement. Kratom's legal limbo has persisted partly because the plant lacks the pharmaceutical industry backing that drives other drug policy debates. Instead, the gas station kratom market cultivates grassroots advocacy groups and cultivates relationships with politicians who benefit financially.
Public health experts warn that unregulated kratom sales normalize botanical opioid use without the safety infrastructure governing prescription medications. Emergency rooms report kratom-related cases, and treatment programs document withdrawal symptoms in users attempting to quit. Yet without clear federal classification, kratom manufacturers avoid accountability.
The industry's push for explicit legal protection rather than mere regulatory forbearance suggests confidence in the new administration's receptiveness. With Mullin holding equity stakes and Kennedy positioned for health policy influence, kratom vendors appear positioned to entrench their market access for years.